Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

84.22 +0.01 (+0.01%)
Official Closing Price Updated: 7:00 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
“We’re In A Stock Pickers Market”
Markets have been oscillating up and down for weeks, creating what resembles a sine wave pattern. As the analyst notes, 
Via Talk Markets
Topics ETFs
Which Is The Healthiest Investment: Merck Or Pfizer
Adeep dive into Merck and Pfizer, two of the biggest pharmaceutical companies out there. 
Via Talk Markets
Topics Stocks / Equities
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Merck & Co Unusual Options Activity For March 10
 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Alarum, and Merck and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
From Merck & Co., Inc.
Via Business Wire
Merck & Co's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial. 
Via Benzinga
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock.
Balancing Dividends and Fundamentals: The Case of MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
A Closer Look at Merck & Co's Options Market Dynamics
 
Via Benzinga
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
Inflation Isn’t Going Away, But These Sectors Don’t Care
The CPI and PPI releases this week came in more or less at estimates - nothing to alarm the talking heads, anyway. They show inflation slowing down but not receding. 
Via Talk Markets
Topics ETFs Economy Stocks / Equities
How Do Investors Really Feel About Merck & Co?
 
Via Benzinga
Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for mid-2025. 
Via Benzinga
Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
From Merck & Co., Inc.
Via Business Wire
Merck Injects $1 Billion To Expand Vaccine Production In US
Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and research investments. 
Via Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains. 
Via MarketBeat
Merck Unveils New Facility to Increase Vaccine Production Capacity
From Merck & Co., Inc.
Via Business Wire
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & Co., Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Institutional Investors Bet $1B on These 4 Stocks—Should You?
Institutional investors snapped up at least $1 billion in shares of each of these four companies in Q4 of 2024 - should you buy as well? 
Via MarketBeat
3 Magnificent S&P 500 Dividend Stocks Down 20% to 63% to Buy and Hold Forever
Great investments are even better and more fruitful when you can buy them at a discount. 
Via The Motley Fool
Topics Stocks
5 Top Stocks to Buy for March
These 5 stocks look rather intriguing at current levels. 
Via The Motley Fool
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals.
Discover MERCK & CO. INC., an undervalued stock. NYSE:MRK showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.